Literature DB >> 19681869

Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages.

D Altavilla1, F Squadrito, A Bitto, F Polito, B P Burnett, V Di Stefano, L Minutoli.   

Abstract

BACKGROUND AND
PURPOSE: The flavonoids, baicalin and catechin, from Scutellaria baicalensis and Acacia catechu, respectively, have been used for various clinical applications. Flavocoxid is a mixed extract containing baicalin and catechin, and acts as a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (LOX) enzymes. The anti-inflammatory activity, measured by protein and gene expression of inflammatory markers, of flavocoxid in rat peritoneal macrophages stimulated with Salmonella enteritidis lipopolysaccharide (LPS) was investigated. EXPERIMENTAL APPROACH: LPS-stimulated (1 microg.mL(-1)) peritoneal rat macrophages were co-incubated with different concentrations of flavocoxid (32-128 microg.mL(-1)) or RPMI medium for different incubation times. Inducible COX-2, 5-LOX, inducible nitric oxide synthase (iNOS) and inhibitory protein kappaB-alpha (IkappaB-alpha) levels were evaluated by Western blot analysis. Nuclear factor kappaB (NF-kappaB) binding activity was investigated by electrophoretic mobility shift assay. Tumour necrosis factor-alpha (TNF-alpha) gene and protein expression were measured by real-time polymerase chain reaction and enzyme-linked immunosorbent assay respectively. Finally, malondialdehyde (MDA) and nitrite levels in macrophage supernatants were evaluated. KEY
RESULTS: LPS stimulation induced a pro-inflammatory phenotype in rat peritoneal macrophages. Flavocoxid (128 microg.mL(-1)) significantly inhibited COX-2 (LPS = 18 +/- 2.1; flavocoxid = 3.8 +/- 0.9 integrated intensity), 5-LOX (LPS = 20 +/- 3.8; flavocoxid = 3.1 +/- 0.8 integrated intensity) and iNOS expression (LPS = 15 +/- 1.1; flavocoxid = 4.1 +/- 0.4 integrated intensity), but did not modify COX-1 expression. PGE(2) and LTB(4) levels in culture supernatants were consequently decreased. Flavocoxid also prevented the loss of IkappaB-alpha protein (LPS = 1.9 +/- 0.2; flavocoxid = 7.2 +/- 1.6 integrated intensity), blunted increased NF-kappaB binding activity (LPS = 9.2 +/- 2; flavocoxid = 2.4 +/- 0.7 integrated intensity) and the enhanced TNF-alpha mRNA levels (LPS = 8 +/- 0.9; flavocoxid = 1.9 +/- 0.8 n-fold/beta-actin) induced by LPS. Finally, flavocoxid decreased MDA, TNF and nitrite levels from LPS-stimulated macrophages. CONCLUSION AND IMPLICATIONS: Flavocoxid might be useful as a potential anti-inflammatory agent, acting at the level of gene and protein expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19681869      PMCID: PMC2765324          DOI: 10.1111/j.1476-5381.2009.00322.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  58 in total

Review 1.  Series introduction: the transcription factor NF-kappaB and human disease.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

2.  Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB.

Authors:  E Niederberger; I Tegeder; G Vetter; A Schmidtko; H Schmidt; C Euchenhofer; L Bräutigam; S Grösch; G Geisslinger
Journal:  FASEB J       Date:  2001-07       Impact factor: 5.191

Review 3.  Inducible nitric oxide synthase and inflammatory diseases.

Authors:  R Zamora; Y Vodovotz; T R Billiar
Journal:  Mol Med       Date:  2000-05       Impact factor: 6.354

4.  (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB.

Authors:  Y L Lin; J K Lin
Journal:  Mol Pharmacol       Date:  1997-09       Impact factor: 4.436

Review 5.  Dual acting anti-inflammatory drugs.

Authors:  S Leone; A Ottani; A Bertolini
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

Review 6.  The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy.

Authors:  Fabio Celotti; Thierry Durand
Journal:  Prostaglandins Other Lipid Mediat       Date:  2003-07       Impact factor: 3.072

Review 7.  Safety of anti-inflammatory treatment--new ways of thinking.

Authors:  K Brune
Journal:  Rheumatology (Oxford)       Date:  2004-02       Impact factor: 7.580

Review 8.  COX-LOX inhibition: current evidence for an emerging new therapy.

Authors:  M M Skelly; C J Hawkey
Journal:  Int J Clin Pract       Date:  2003-05       Impact factor: 2.503

9.  The high-output nitric oxide pathway: role and regulation.

Authors:  Q Xie; C Nathan
Journal:  J Leukoc Biol       Date:  1994-11       Impact factor: 4.962

10.  The shunt from the cyclooxygenase to lipoxygenase pathway in human osteoarthritic subchondral osteoblasts is linked with a variable expression of the 5-lipoxygenase-activating protein.

Authors:  Kelitha Maxis; Aline Delalandre; Johanne Martel-Pelletier; Jean-Pierre Pelletier; Nicolas Duval; Daniel Lajeunesse
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more
  28 in total

1.  Flavocoxid attenuates gentamicin-induced nephrotoxicity in rats.

Authors:  Dalia H El-Kashef; Asmaa E El-Kenawi; Ghada M Suddek; Hatem A Salem
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-08-15       Impact factor: 3.000

2.  Flavocoxid, a dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, reduces pancreatic damage in an experimental model of acute pancreatitis.

Authors:  F Polito; A Bitto; N Irrera; F Squadrito; C Fazzari; L Minutoli; D Altavilla
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

3.  Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia.

Authors:  D Altavilla; L Minutoli; F Polito; N Irrera; S Arena; C Magno; M Rinaldi; B P Burnett; F Squadrito; A Bitto
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

4.  Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases: "reverse pharmacology" and "bedside to bench" approach.

Authors:  Bharat B Aggarwal; Sahdeo Prasad; Simone Reuter; Ramaswamy Kannappan; Vivek R Yadev; Byoungduck Park; Ji Hye Kim; Subash C Gupta; Kanokkarn Phromnoi; Chitra Sundaram; Seema Prasad; Madan M Chaturvedi; Bokyung Sung
Journal:  Curr Drug Targets       Date:  2011-10       Impact factor: 3.465

5.  Structure-activity relationship of pyrrolyl diketo acid derivatives as dual inhibitors of HIV-1 integrase and reverse transcriptase ribonuclease H domain.

Authors:  Giuliana Cuzzucoli Crucitti; Mathieu Métifiot; Luca Pescatori; Antonella Messore; Valentina Noemi Madia; Giovanni Pupo; Francesco Saccoliti; Luigi Scipione; Silvano Tortorella; Francesca Esposito; Angela Corona; Marta Cadeddu; Christophe Marchand; Yves Pommier; Enzo Tramontano; Roberta Costi; Roberto Di Santo
Journal:  J Med Chem       Date:  2015-02-11       Impact factor: 7.446

6.  A combination of Scutellaria baicalensis and Acacia catechu extracts for short-term symptomatic relief of joint discomfort associated with osteoarthritis of the knee.

Authors:  Bahram H Arjmandi; Lauren T Ormsbee; Marcus L Elam; Sara C Campbell; Nader Rahnama; Mark E Payton; Ken Brummel-Smith; Bruce P Daggy
Journal:  J Med Food       Date:  2014-03-10       Impact factor: 2.786

7.  Baicalin in flavocoxid may act against hepatitis B virus via a pro-inflammatory pathway.

Authors:  Salvatore Chirumbolo
Journal:  Inflamm Res       Date:  2017-11-13       Impact factor: 4.575

8.  A dual inhibitor of cyclooxygenase and 5-lipoxygenase protects against kainic acid-induced brain injury.

Authors:  Letteria Minutoli; Herbert Marini; Mariagrazia Rinaldi; Alessandra Bitto; Natasha Irrera; Gabriele Pizzino; Giovanni Pallio; Margherita Calò; Elena Bianca Adamo; Vincenzo Trichilo; Monica Interdonato; Federica Galfo; Francesco Squadrito; Domenica Altavilla
Journal:  Neuromolecular Med       Date:  2015-04-19       Impact factor: 3.843

Review 9.  Medical Plant Extracts for Treating Knee Osteoarthritis: a Snapshot of Recent Clinical Trials and Their Biological Background.

Authors:  Sonja M Walzer; Daniela Weinmann; Stefan Toegel
Journal:  Curr Rheumatol Rep       Date:  2015-08       Impact factor: 4.592

10.  Flavocoxid Ameliorates Aortic Calcification Induced by Hypervitaminosis D3 and Nicotine in Rats Via Targeting TNF-α, IL-1β, iNOS, and Osteogenic Runx2.

Authors:  Ahmed E Amer; George S G Shehatou; Hassan A El-Kashef; Manar A Nader; Ahmed R El-Sheakh
Journal:  Cardiovasc Drugs Ther       Date:  2021-07-26       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.